These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30190568)

  • 1. Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo.
    Cardo L; Nawroth I; Cail PJ; McKeating JA; Hannon MJ
    Sci Rep; 2018 Sep; 8(1):13342. PubMed ID: 30190568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron(II) supramolecular helicates interfere with the HIV-1 Tat-TAR RNA interaction critical for viral replication.
    Malina J; Hannon MJ; Brabec V
    Sci Rep; 2016 Jul; 6():29674. PubMed ID: 27405089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discoveries of Tat-TAR interaction inhibitors for HIV-1.
    Yang M
    Curr Drug Targets Infect Disord; 2005 Dec; 5(4):433-44. PubMed ID: 16535863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of HIV-1 TAR RNA-ligand complexes.
    Mitrasinovic PM; Tomar JS; Nair MS; Barthwal R
    Med Chem; 2011 Jul; 7(4):301-8. PubMed ID: 21574948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein.
    Davidson A; Leeper TC; Athanassiou Z; Patora-Komisarska K; Karn J; Robinson JA; Varani G
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):11931-6. PubMed ID: 19584251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 TAR element revertant viruses define RNA structures required for efficient viral gene expression and replication.
    Harrich D; Mavankal G; Mette-Snider A; Gaynor RB
    J Virol; 1995 Aug; 69(8):4906-13. PubMed ID: 7609059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery.
    Chavali SS; Bonn-Breach R; Wedekind JE
    J Biol Chem; 2019 Jun; 294(24):9326-9341. PubMed ID: 31080171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication.
    Hwang S; Tamilarasu N; Kibler K; Cao H; Ali A; Ping YH; Jeang KT; Rana TM
    J Biol Chem; 2003 Oct; 278(40):39092-103. PubMed ID: 12857725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.
    Lalonde MS; Lobritz MA; Ratcliff A; Chamanian M; Athanassiou Z; Tyagi M; Wong J; Robinson JA; Karn J; Varani G; Arts EJ
    PLoS Pathog; 2011 May; 7(5):e1002038. PubMed ID: 21625572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.
    Wu-Baer F; Sigman D; Gaynor RB
    Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7153-7. PubMed ID: 7638159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interactions and recognition of cyclic peptide mimetics of Tat with HIV-1 TAR RNA: a molecular dynamics simulation study.
    Li CH; Zuo ZC; Su JG; Xu XJ; Wang CX
    J Biomol Struct Dyn; 2013 Mar; 31(3):276-87. PubMed ID: 22943434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary Element Interaction in HIV-1 TAR.
    Krawczyk K; Sim AY; Knapp B; Deane CM; Minary P
    J Chem Inf Model; 2016 Sep; 56(9):1746-54. PubMed ID: 27500460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences.
    Braddock M; Cannon P; Muckenthaler M; Kingsman AJ; Kingsman SM
    J Virol; 1994 Jan; 68(1):25-33. PubMed ID: 8254735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat.
    Muniz L; Egloff S; Ughy B; Jády BE; Kiss T
    PLoS Pathog; 2010 Oct; 6(10):e1001152. PubMed ID: 20976203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation.
    Richter S; Cao H; Rana TM
    Biochemistry; 2002 May; 41(20):6391-7. PubMed ID: 12009901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.
    Roy S; Delling U; Chen CH; Rosen CA; Sonenberg N
    Genes Dev; 1990 Aug; 4(8):1365-73. PubMed ID: 2227414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human chromosome 12-associated 83-kilodalton cellular protein specifically binds to the loop region of human immunodeficiency virus type 1 trans-activation response element RNA.
    Hart CE; Saltrelli MJ; Galphin JC; Schochetman G
    J Virol; 1995 Oct; 69(10):6593-9. PubMed ID: 7666565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celastrol inhibits Tat-mediated human immunodeficiency virus (HIV) transcription and replication.
    Narayan V; Ravindra KC; Chiaro C; Cary D; Aggarwal BB; Henderson AJ; Prabhu KS
    J Mol Biol; 2011 Jul; 410(5):972-83. PubMed ID: 21763500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.
    Du Z; Lind KE; James TL
    Chem Biol; 2002 Jun; 9(6):707-12. PubMed ID: 12079782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.